TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01290497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 5 x 2.5 ml
Description: 5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 1 x 5 ml
Description: 1 intraarticular administration of Adant® 5ml
Study: NCT03171116

Intervention type: OTHER
Intervention: none intervention
Description: it is not an interventional study; it is an observational study
Study: NCT03180554

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
Study: NCT01290497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 2 x 5 ml
Description: 2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
Study: NCT02065414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Advance Gum Defense

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth rinse containing Chlorhexidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouth rinse containing 5% Hydroalcohol
Study: NCT00477204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Simvastatin
Description: Ezetimibe (10mg)/Simvastatin (20mg)
Study: NCT04616846

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral venous ultrasound
Description: Screening for VTE from D7 to 42
Study: NCT02147067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine 1,000 mg twice daily
Study: NCT03180554

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).

Intervention type: OTHER
Group type: OTHER
Intervention: Motivational nondirective resonance breathing (MNRB)
Description: Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.

Intervention type: OTHER
Group type: OTHER
Intervention: Motivational nondirective resonance breathing (MNRB)
Description: Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
Study: NCT02902653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Description: hourly titrated misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: Administration of 25 microgs every 6 hours, maximum 150 microgr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal dinoprostone
Description: Vaginal delivery system of 10mg of dinoprostone
Study: NCT02217488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02147067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02619305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social network tie
Description: Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
Study: NCT00427778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incontinence ring
Description: Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incontinence ring
Description: Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra.
Study: NCT01101997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT04604470

Intervention type: OTHER
Intervention: Decision tool
Description: no intervention.

Intervention type: OTHER
Intervention: Decision tool
Description: no intervention.
Study: NCT03110263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent internet-based self-help
Description: Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based sleep restriction
Description: Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
Study: NCT01316887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125/25 mcg once-daily GSK573719/GW642444
Description: GSK573719/GW642444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125mcg once-daily GSK573719
Description: GSK573719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once-daily
Description: inactive
Study: NCT03336697

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
Study: NCT00107978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day, IV for up to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
Study: NCT01391429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Decision Support Tool
Description: Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
Study: NCT02099136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies
Study: NCT04696133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fine motor skills
Description: stretching and strengthening exercises in addition to exercises to enhance fine motor skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory integration
Description: * Tactile stimulation~* Proprioceptive stimulation
Study: NCT00739609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-D-tryptophan
Description: D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
Study: NCT01980602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Exercise program
Study: NCT01637285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose C

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose D
Study: NCT02647788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Ibuprofen
Description: After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Codeine
Description: After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
Study: NCT01053338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
Study: NCT04656366

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
Study: NCT05514743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 minute walk test , Blood pressure monitoring
Description: Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 minute walk test , Blood pressure monitoring
Description: Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days.
Study: NCT03942926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive sirolimus for 6 months.
Study: NCT02334098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplemented drink
Description: The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment.
Study: NCT04198948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
Study: NCT06224010

Intervention type: OTHER
Intervention: Respiratory drive and effort assessment
Description: The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients

Intervention type: OTHER
Intervention: Respiratory drive and effort assessment
Description: The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients

Intervention type: OTHER
Intervention: Respiratory drive and effort assessment
Description: The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
Study: NCT03520062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: Treatment with Liraglutide (3.0mg per day) for \~6 weeks
Study: NCT02334098

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smartfish
Description: Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
Study: NCT04015752

Intervention type: DIAGNOSTIC_TEST
Intervention: culture from infected site
Description: ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.

Intervention type: DIAGNOSTIC_TEST
Intervention: culture from infected site
Description: ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.

Intervention type: DIAGNOSTIC_TEST
Intervention: culture from infected site
Description: ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
Study: NCT03718169

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
Study: NCT04246502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Pyrotinib
Description: Pyrotinib 400mg orally daily until progressive disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine,Trastuzumab, and Pertuzumab
Description: as instruction
Study: NCT04787861

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motorized movement therapy
Description: The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motorized movement therapy
Description: The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
Study: NCT00755950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 280 mg three times daily for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 420 mg three times daily for four weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: Lactose monohydrate 326.95 mg three times daily for four weeks
Study: NCT01897571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Study: NCT00359177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769
Description: GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769
Description: GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
Study: NCT02886884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion